Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160153 | 0.80 | — | — | |
| SCHEMBL4460999 | 0.79 | HPGD (0.40) | HPGDSMN1; SMN2NQO1 | |
| SCHEMBL4475588 | 0.78 | L3MBTL1 (0.35) | HPGDSMN1; SMN2NQO1 | |
| SCHEMBL17316735 | 0.77 | CNR2 (0.35) | — | |
| SCHEMBL9480869 | 0.75 | GAA (0.39) | HPGDSMN1; SMN2 | |
| SCHEMBL2066706 | 0.73 | HPGD (0.33) | HPGDSMN1; SMN2 | |
| SCHEMBL22683404 | 0.73 | CTSS (0.32) | — | |
| SCHEMBL2067011 | 0.72 | SMN1; SMN2 (0.34) | HPGDSMN1; SMN2 | |
| SCHEMBL2069418 | 0.71 | AOC3 (0.34) | HPGDSMN1; SMN2NQO1 | |
| SCHEMBL4729044 | 0.69 | NQO1 (0.36) | HPGDNQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8575156-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HPGD 52/4885SMN1; SMN2 3642/4885LRRK2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.